Doxorubicin Transdrug®: Significant increased survival rate in patients with advanced hepatocellular carcinoma treated … (Business Wire via Yahoo! Finance)

PARIS—-BioAlliance Pharma SA , a company dedicated to the treatment and supportive care of cancer and AIDS patients, today announces positive survival data in its phase II clinical trial with doxorubicin Transdrug® in patients with advanced hepatocellular carcinoma .
(read here…)

Related items

• Phase II clinical trial results of Doxorubicin Transdrug announced (News-Medical-Net)
• Doxorubicin Transdrug(R): Significant Increased Survival Rate In Patients With Advanced Hepatocellular Carcinoma … (Medical News Today)
• Going For Gold With A Novel Interventional Radiology Treatment For Pancreatic Cancer (Medical News Today)
• Going For Gold With Novel Interventional Radiology Treatment For Pancreatic Cancer (redOrbit)
• Qatar-based expert makes device for cancer treatment (The Peninsula)

Tags: aids patients, bioalliance pharma, cancer, care, company, doxorubicin, hepatocellular carcinoma, nano, nanotech, nanotechnology, PARIS----BioAlliance, Pharma, survival data, Technology, treatment

This entry was posted on Tuesday, December 8th, 2009 at 10:53 pm and is filed under Technology.